A systematic review of plant-derived natural compounds for anxiety disorders

Current Topics in Medicinal Chemistry

Volumn 16, Issue 17, 2016, Pages 1924-1942

  Farzaei, Mohammad Hosein ^a   Bahramsoltani, Roodabeh ^b   Rahimi, Roja ^c   Abbasabadi, Faezeh ^a   Abdollahi, Mohammad ^c,d  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety; Anxiolytic; Complementary and alternative medicine; Medicinal plants; Phytochemical; Plant derived natural agents; Review

Indexed keywords

3 HEXENOL; ALPHA ASARONE; ALSTONINE; ANNOMONTINE; BERBERINE; CHLOROGENIC ACID; CHOLECYSTOKININ; CURCUMIN; DITETRAHYDROPALMATINE; ELLAGIC ACID; EPICATECHIN; ERYSOTHRINE; GASTRODIN; GELSEMINE; GELSENICINE; GELSEVIRINE; KOUMINE; METHYL ISOEUGENOL; MITRAGYNINE; PIPERINE; PIPLARTINE; PLANT MEDICINAL PRODUCT; PSYCHOLLATINE; SANJOININE A; SEROTONIN; SINAPIC ACID; TETRAHYDROPALMATINE; THEANINE; THYMOQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BIOLOGICAL PRODUCT;

AMYGDALA; ANXIETY DISORDER; ARTICLE; BINDING AFFINITY; DRUG MECHANISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; PATHOGENESIS; PHYTOCHEMISTRY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTONINERGIC SYSTEM; STRESS; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; WITHDRAWAL SYNDROME; ANXIETY DISORDERS; METABOLISM;

ANXIETY DISORDERS; BIOLOGICAL PRODUCTS; HUMANS; PHYTOCHEMICALS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84974661275     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160204121039     Document Type: Article

References (154)

1. American Psychiatric Association. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Text Revision. 5th ed.; American Psychiatric Association, Ed.; Washington (DC), 2013.
2. Candy, B.; Jackson, K.C.; Jones, L.; Tookman, A.; King, M. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane. Database. Syst. Rev., 2012, 10, CD004596.
3. Pillay, N.S.; Stein, D.J. Emerging anxiolytics. Expert. Opin. Emerg. Drugs., 2007, 12, 541-554.
4. Abbo, C.; Kinyanda, E.; Kizza, R.B.; Levin, J.; Ndyanabangi, S.; Stein, D.J. Prevalence comorbidity and predictors of anxiety disorders in children and adolescents in rural north-eastern Uganda. Child. Adolesc. Psychiatry. Ment. health., 2013, 7, 21.
5. Rapaport, M.H.; Clary, C.; Fayyad, R.; Endicott, J. Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry., 2005, 162(6), 1171-8.
6. Ipser, J.C.; Stein, D.J. A systematic review of the quality and impact of anxiety disorder meta-analyses. Curr. Psychiatry. Rep., 2009, 11, 302-309.
7. Zarafshan, H.; Mohammadi, M.R.; Salmanian, M. Prevalence of Anxiety Disorders among Children and Adolescents in Iran: A Systematic Review. Iran. J. psychiatry., 2015, 10(1), 1-7.
8. Baldwin, D.S.; Pallanti, S.; Zwanzger, P. Developing a European research network to address unmet needs in anxiety disorders. Neurosci. Biobehav. Rev., 2013, 37(10 Pt 1), 2312-7.
9. Beck, A.T. The evolution of the cognitive model of depression and its neurobiological correlates. Am. J. Psychiatry., 2008, 165, 969-977.
10. Bandelow, B.; Sher, L.; Bunevicius, R.; Hollander, E.; Kasper, S.; Zohar, J.; Moller, H.J. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD, PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder, and posttraumatic stress disorder in primary care. Int. J. Psychiatry. Clin. Pract., 2012, 16(2), 77-84.
11. Baldwin, D.S.; Anderson, I.M.; Nutt, D.J.; Allgulander, C.; Bandelow, B.; den Boer, J.A.; Christmas, D.M.; Davies, S.; Fineberg, N.; Lidbetter, N.; Malizia, A.; McCrone, P.; Nabarro, D.; O'Neill, C.; Scott, J.; van der Wee, N.; Wittchen, H.U. Evidence-based pharmacological treatment of anxiety disorders, posttraumatic stress* disorder, and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J. Psychopharmacol., 2014, 28(5), 403-439.
12. Risbrough, V.B.; Stein, M.B. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm. Behav., 2006, 50(4), 550-61.
13. Duval, E.R.; Javanbakht, A.; Liberzon, I. Neural circuits in anxiety and stress disorders: a focused review. Ther. Clin. Risk. Manag., 2015, 11, 115-26.
14. Straube, T.; Glauer, M.; Dilger, S.; Mentzel, H.J.; Miltner, W.H. Effects of cognitive-behavioral therapy on brain activation in specific phobia. Neuroimage. 2006, 29(1), 125-135.
15. Stein, M.B.; Steckler, T. Behavioral neurobiology of anxiety and its treatment. Vol. 2. Springer Science & Business Media., 2010.
16. de Kloet, E.R.; Joels, M.; Holsboer, F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci., 2005, 6(6), 463-475.
17. Cerqueira, J.J.; Almeida, O.F.; Sousa, N. The stressed prefrontal cortex. Left? Right!. Brain. Behav. Immun., 2008, 22(5), 630-638.
18. Cerqueira, J.J.; Mailliet, F.; Almeida, O.F.; Jay, T.M.; Sousa, N. The prefrontal cortex as a key target of the maladaptive response to stress. J. Neurosci., 2007, 27(11), 2781-2787.
19. Ohno, Y. New insight into the therapeutic role of 5-HT1A receptors in central nervous system disorders. Cent. Nerv. Syst. Agents. Med. Chem., 2010, 10, 148-57.
20. Gelfuso, E.A.; Rosa, D.S.; Fachin, A.L.; Mortari, M.R.; Cunha, A.O.; Beleboni, R.O. Anxiety: a systematic review of neurobiology, traditional pharmaceuticals and novel alternatives from medicinal plants. CNS. Neurol. Disord. Drug. Targets., 2014, 13(1), 150-65.
21. Murphy S.E. Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). Curr. Pharm. Des., 2010, 16, 1990-7.
22. Barbalho, C.A.; Nunes-de-Souza, R.L.; Canto-de-Souza, A. Similar anxiolytic-like effects following intra-amygdala infusions of benzodiazepine receptor agonist and antagonist: evidence for the release of an endogenous benzodiazepine inverse agonist in mice exposed to elevated plus-maze test. Brain. Res., 2009, 1267, 65-76.
23. Heldt, S.A.; Mou, L.; Ressler, K.J. In vivo knockdown of GAD67 in the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam in mice. Transl. Psychiatry., 2012, 2, e181.
24. B receptor. Adv. Pharmacol., 2010, 58, 1-18.
25. Eser, D.; Baghai, T.C.; Schule, C.; Nothdurfter, C.; Rupprecht, R. Neuroactive steroids as endogenous modulators of anxiety. Curr. Pharm. Des., 2008, 14(33), 3525-3533.
26. Miyasaka, K.; Kobayashi, S.; Ohta, M.; Kanai, S.; Yoshida, Y.; Nagata, A.; Matsui, T.; Noda, T.; Takiguchi, S.; Takata, Y.; Kawanami, T.; Funakoshi, A. Anxiety-related behaviors in cholecystokinin-A, B, and AB receptor gene knockout mice in the plus-maze. Neurosci. Lett., 2002, 335, 115-118.
27. Van't Veer, A.; Carlezon, W.A. Role of κ-opioid receptors in stress and anxiety-related behavior. Psychopharmacol., 2013, 229(3), 435-452.
28. Hill, M.N.; Gorzalka, B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS. Neurol. Disord. Drug. Targets., 2009, 8(6), 451-458.
29. Wu, G.; Feder, A.; Wegener, G.; Bailey, C.; Saxena, S.; Charney, D.; Mathe, A.A. Central functions of neuropeptide Y in mood and anxiety disorders. Expert. Opin. Ther. Targets., 2011, 15(11), 1317-1331.
30. Ballon, D.; Anxiety Disorders: An Information Guide. Toronto, Canada: Centre for Addiction and Mental Health., 2008.
31. Henderson, M.; MacGregor, E.; Sykes, N.; Hotopf, M. The use of benzodiazepines in palliative care. Palliat. Med., 2006, 20, 407-12.
32. Roth, A.J.; Massie, M.J. Anxiety and its management in advanced cancer. Current. Opin. Support. Palliative. Care., 2007, 1, 50-6.
33. Schneier, F.R. Pharmacotherapy of social anxiety disorder. Expert. Opin. Pharmacother., 2011, 12(4), 615-25.
34. Christmas, D.; Hood, S.; Nutt, D. Potential novel anxiolytic drugs. Curr. Pharm. Des., 2008, 14, 3534-3546.
35. Harrison, N.; Wallace, M.B.; Wit, H. In: Barbiturates, 2008. Reference: Available from: URL: http://www.acnp.org/g4/GN401000173/CH169.html.
36. Lader, M. Benzodiazepines revisited-will we ever learn?. Addict., 2011, 106(12), 2086-2109.
37. Auchewski, L.; Andreatini, R.; Galduroz, J.C.F.; de Lacerda, R.B. Evaluation of the medical orientation for the benzodiazepine side effects. Rev. Bras. Psiquiatr., 2004, 26(1), 24-31.
38. Lader, M.H. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. Eur. Neuropsychopharmacol., 1999, 9(6), S399-405.
39. Koen, N.; Stein, D.J. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin. Neurosci., 2011, 13(4), 423-437.
40. Farach, F.J.; Pruitt, L.D.; Jun, J.J.; Jerud, A.B.; Zoellner, L.A.; Roy-Byrne, P.P. Pharmacological treatment of anxiety disorders: current treatments and future directions. J. Anxiety. Disord., 2012, 26(8), 833-843.
41. Schmitt, R.; Gazalle, F.K.; de Lima, M.S.; Cunha, A.; Souza, J.; Kapczinski, F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev. Bras. Psiquiatr., 2005, 27(1), 18-24.
42. Bourin, M.; Briley, M. Sedation, an unpleasant, undesirable and potentially dangerous side-effect of many psychotropic drugs. Hum. Psychopharmacol., 2004, 19(2), 135-9.
43. Zahreddine, N.; Richa, S. Non-Antidepressant Treatment of Generalized Anxiety Disorder. Curr. Clin. Pharmacol., 2013. [Epub ahead of print]
44. Nirumand, M.C.; Farzaei, M.H.; Amin, G. Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review. J. Tradit. Chin. Med., 2015, 35(1), 104-9.
45. Farzaei, M.H.; Rahimi, R.; Abdollahi, M. The role of dietary polyphenols in the management of inflammatory bowel disease. Curr. Pharm. Biotechnol., 2015, 16, 196-210.
46. Ang-Lee, M.K.; Moss, J.; Yuan, C.S. Herbal medicines and perioperative care. JAMA., 2001, 286(2), 208-216.
47. Yu, C.H.; Ishii, R.; Yu, S.C.; Takeda, M. Yokukansan and its ingredients as possible treatment options for schizophrenia. Neuropsychiatr. Dis. Treat., 2014, 10, 1629-34.
48. Rahimi, R.; Nikfar, S.; Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis.Prog. Neuropsychopharmacol. Biol. Psychiatry., 2009, 33(1), 118-27.
49. Lakhan, S.E.; Vieira, K.F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr., 2010, 9, 42.
50. Alramadhan, E.; Hanna, M.S.; Hanna, M.S.; Goldstein, T.A.; Avila, S.M.; Weeks, B.S. Dietary and botanical anxiolytics. Med. Sci. Monit., 2012, 18, 40-48.
51. Bahramsoltani, R.; Farzaei, M.H.; Sarbandi Farahani, M.; Rahimi, R. Phytochemical constituents as future antidepressants: a comprehensive review. Rev. Neurosci., 2015, in press.
52. Sarbandi Farahani, M.; Bahramsoltani, R.; Farzaei, M.H.; Abdollahi, M.; Rahimi, R. Plant-derived natural medicines for the management of depression: an overview of mechanisms of action. Rev. Neurosci., 2015, 26(3), 305-21.
53. Barbosa-Filho, J.M.; Piuvezam, M.R.; Moura, M.D.; Silva, M.S.; Batista Lima, K.V. Leitao da-Cunha, E.V., Fechine, I.M., Takemura, O.S. Anti-inflammatory activity of alkaloids, a twentycentury review. Braz. J. Pharmacogn., 2006, 16(1), 109-139.
54. Peng, W.H.; Wu, C.R.; Chen, C.S.; Chen, C.F.; Leu, Z.C.; Hsieh, M.T. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: Interaction with drugs acting at 5-HT receptors. Life. Sci., 2004, 75(20), 2451-62.
55. Leung, W.C.; Zheng, H.; Huen, M.; Law, S.L.; Xue, H. Anxiolyticlike action of orally administered dl-tetrahydropalmatine in elevated plus-maze. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2003, 27(5), 775-9.
56. Henkes, H.; Franz, M.; Kendall, O.; Monroe, J.; Legaspi, A.; Le-Doux, J.; Haese, C.; Williams, D.; McCall, S.; Johnson, A.D.; Ceremuga, T.E. Evaluation of the anxiolytic properties of Tetrahydropalmatine, a Corydalis yanhusuo compound, in the male Sprague-Dawley rat. AANA. J., 2011, 79(4), 75-80.
57. Mao, Q.Q.; Xian, Y.F.; Ip, S.P.; Che, C.T. Involvement of serotonergic system in the antidepressant-like effect of piperine. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2011, 35(4), 1144-7.
58. Wattanathorn, J.; Chonpathompikunlert, P.; Muchimapura, S.; Priprem, A.; Tankamnerdthai, O. Piperine, the potential functional food for mood and cognitive disorders. Food. Chem. Toxicol., 2008, 46(9), 3106-10.
59. Khom, S.; Strommer, B.; Schoffmann, A.; Hintersteiner, J.; Baburin, I.; Erker, T.; Schwarz, T.; Schwarzer, C.; Zaugg, J.; Hamburger, M.; Hering, S. GABAA receptor modulation by piperine and a non-TRPV1 activating derivative. Biochem. Pharmacol., 2013, 85(12), 1827-36.
60. Liu, M.; Huang, H.H.; Yang, J.; Su, Y.P.; Lin, H.W.; Lin, L.Q.; Liao, W.J.; Yu, C.X. The active alkaloids of Gelsemium elegans Benth. are potent anxiolytics. Psychopharmacology (Berl)., 2013, 225(4), 839-51.
61. Salvamani, S.; Gunasekaran, B.; Shaharuddin, N.A.; Ahmad, S.A.; Shukor, M.Y. Antiartherosclerotic effects of plant flavonoids. Biomed. Res. Int., 2014, 480258.
62. Solati, J.; Yaghmaei, P.; Mohammdadi, K. Role of the 5-HT 1A serotonergic system in anxiolytic-like effects of silymarin. Neurophysiol., 2012, 44(1), 49-55.
63. de Carvalho, R.S.; Duarte, F.S.; de Lima, T.C. Involvement of GABAergic non-benzodiazepine sites in the anxiolytic-like and sedative effects of the flavonoid baicalein in mice. Behav. Brain. Res., 2011, 221(1), 75-82.
64. Liao JF, Hung WY, Chen CF. Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice. Eur. J. Pharmacol., 2003, 464(2-3), 141-6.
65. Grundmann, O.; Nakajima, J.; Kamata, K.; Seo, S.; Butterweck, V. Kaempferol from the leaves of Apocynum venetum possesses anxiolytic activities in the elevated plus maze test in mice. Phytomedicine., 2009, 16(4), 295-302.
66. Vissiennon, C.; Nieber, K.; Kelber, O.; Butterweck, V. Route of administration determines the anxiolytic activity of the flavonols kaempferol, quercetin and myricetin--are they prodrugs?. J. Nutr. Biochem., 2012, 23(7), 733-40.
67. Mahalaxmi, Mohan.; Swati, S.; Jadhav, Veena, S.; Kasture, B. Effect of myricetin on behavioral paradigms of anxiety. Pharm. Biol., 2009, 47(10).
68. Viola, H.; Wasowski, C.; Levi de Stein, M.; Wolfman, C.; Silveira, R.; Dajas, F.; Medina, J.H.; Paladini, A.C. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta. Med., 1995, 61(3), 213-6.
69. Avallone, R.; Zanoli, P.; Puia, G.; Kleinschnitz, M.; Schreier, P.; Baraldi, M. Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochem. Pharmacol., 2000, 59(11), 1387-94.
70. Zanoli, P.; Avallone, R.; Baraldi, M. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia., 2000, 71(Suppl 1), S117-23.
71. Kuribara, H.; Stavinoha, W.B.; Maruyama, Y. Behavioural pharmacological characteristics of honokiol, an anxiolytic agent present in extracts of Magnolia bark, evaluated by an elevated plus-maze test in mice. J. Pharm. Pharmacol., 1998, 50(7), 819-26.
72. Kuribara, H.; Kishi, E.; Kimura, M.; Weintraub, S.T.; Maruyama, Y. Comparative assessment of the anxiolytic-like activities of honokiol and derivatives. Pharmacol. Biochem. Behav., 2000, 67(3), 597-601.
73. Sulakhiya, K.; Kumar, P.; Gurjar, S.S.; Barua, C.C.; Hazarika, N.K. Beneficial effect of honokiol on lipopolysaccharide induced anxiety-like behavior and liver damage in mice. Pharmacol. Biochem. Behav., 2015, 132, 79-87.
74. Han, H.; Jung, J.K.; Han, S.B.; Nam, S.Y.; Oh, K.W.; Hong, J.T. Anxiolytic-like effects of 4-O-methylhonokiol isolated from Magnolia officinalis through enhancement of GABAergic transmission and chloride influx. J. Med. Food., 2011, 14(7-8), 724-31.
75. Haider, S.; Naqvi, F.; Batool, Z.; Tabassum, S.; Sadir, S.; Liaquat, L.; Naqvi, F.; Zuberi, N. A.; Shakeel, H.; Perveen, T. Pretreatment with curcumin attenuates anxiety while strengthens memory performance after one short stress experience in male rats. Brain. Res. Bull., 2015, 115, 1-8.
76. Panahi, Y.; Badeli, R.; Karami, G.R.; Sahebkar, A. Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res., 2015, 29(1), 17-21.
77. Benammi, H.; El Hiba, O.; Romane, A.; Gamrani, H. A blunted anxiolytic like effect of curcumin against acute lead induced anxiety in rat: Involvement of serotonin. Acta. Histochem., 2014, 116(5), 920-5.
78. Chimakurthy, J.; Talasila, M. Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol. Neurosci., 2010, 3(2), 239-44.
79. Gilhotra, N.; Dhingra, D. GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain. Res., 2010, 1352, 167-75.
80. Jung, J.W.; Yoon, B.H.; Oh, H.R.; Ahn, J.H.; Kim, S.Y.; Park, S.Y.; Ryu, J.H. Anxiolytic-like effects of Gastrodia elata and its phenolic constituents in mice. Biol. Pharm. Bull., 2006, 29(2), 261-5.
81. Mansouri, M.T.; Soltani, M.; Naghizadeh, B.; Farbood, Y.; Mashak, A.; Sarkaki, A. A possible mechanism for the anxiolyticlike effect of gallic acid in the rat elevated plus maze. Pharmacol. Biochem. Behav., 2014, 117, 40-6.
82. Scheepens, A.; Bisson, J.F.; Skinner, M. P-Coumaric acid activates the GABA-a receptor in vitro and is orally anxiolytic in Vivo. Phytother. Res., 2014, 28(2), 207-11.
83. Takeda, H.; Tsuji, M.; Miyamoto, J.; Masuya, J.; Iimori, M.; Matsumiya, T. Caffeic acid produces antidepressive-and/or anxiolytic-like effects through indirect modulation of the alpha 1Aadrenoceptor system in mice. Neuroreport., 2003, 14(7), 1067-70.
84. Vincken, J.P.; Heng, L.; de Groot, A.; Gruppen, H. Saponins, classification and occurrence in the plant kingdom. Phytochemistry, 2007, 68(3), 275-297.
85. Kim, T.W.; Choi, H.J.; Kim, N.J.; Kim, D.H. Anxiolytic-like effects of ginsenosides Rg3 and Rh2 from red ginseng in the elevated plus-maze model. Planta. Med., 2009, 75(8), 836-9.
86. Oh, H.A.; Choi, H.J.; Kim, N.J.; Kim, D.H. Anti-stress effect of astragaloside IV in immobilized mice. J. Ethnopharmacol., 2014, 153(3), 928-32.
87. Jung, Y.H.; Ha, R.R.; Kwon, S.H.; Hong, S.I.; Lee, K.H.; Kim, S.Y.; Lee, S.Y.; Jang, C.G. Anxiolytic effects of Julibroside C1 isolated from Albizzia julibrissin in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2013, 44, 184-92.
88. Fajemiroye, J.O.; Galdino, P.M.; Florentino, I.F.; Da Rocha, F.F.; Ghedini, P.C.; Polepally, P.R.; Zjawiony, J.K.; Costa, E.A. Plurality of anxiety and depression alteration mechanism by oleanolic acid. J. Psychopharmacol., 2014, 28(10), 923-34.
89. Gershenzon, J.; Dudareva, N. The function of terpene natural products in the natural world. Nat. Chem. Biol., 2007, 3(7), 408-14.
90. Bakkali, F.; Averbeck, S.; Averbeck, D.; Idaomar, M. Biological effects of essential oils--a review. Food. Chem. Toxicol., 2008, 46(2), 446-75.
91. Kubacka, M.; Librowski, T.; Czarnecki, R.; Frackowiak, B.; Lochyński, S. Anticonvulsant and antidepressant activity of the selected terpene GABA derivatives in experimental tests in mice. Pharmacol. Rep., 2006, 58(6), 936-43.
92. Campos, A.C.; Guimaraes, F.S. Terpene depression Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl)., 2008, 199(2), 223-30.
93. Campos, A.C.; Ferreira, F.R.; Guimaraes, F.S. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors. J. Psychiatr. Res., 2012, 46(11), 1501-10.
94. Campos, A.C.; Ortega, Z.; Palazuelos, J.; Fogaca, M.V.; Aguiar, D.C.; Diaz-Alonso, J.; Ortega-Gutierrez, S.; Vazquez-Villa, H.; Moreira, F.A.; Guzman, M.; Galve-Roperh, I.; Guimaraes, F.S. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol., 2013, 16(6), 1407-19.
95. Fogaca, M.V.; Reis, F.M.; Campos, A.C.; Guimaraes, F.S. Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience. Eur. Neuropsychopharmacol., 2014, 24(3), 410-9.
96. Gomes, F.V.; Resstel, L.B.; Guimaraes, F.S. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl)., 2011, 213(2-3), 465-73.
97. Moreira, F.A.; Aguiar, D.C.; Guimaraes, F.S. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2006, 30(8), 1466-71.
98. Marinho, A.L.; Vila-Verde, C.; Fogaca, M.V.; Guimaraes, F.S. Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences. Behav. Brain. Res., 2015, 286, 49-56.
99. Crippa, J.A.; Derenusson, G.N.; Ferrari, T.B.; Wichert-Ana, L.; Duran, F.L.; Martin-Santos, R.; Simoes, M.V.; Bhattacharyya, S.; Fusar-Poli, P.; Atakan, Z.; Santos Filho, A.; Freitas-Ferrari, M.C.; McGuire, P.K.; Zuardi, A.W.; Busatto, G.F.; Hallak, J.E. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J. Psychopharmacol., 2011, 25(1), 121-30.
100. Bergamaschi, M.M.; Queiroz, R.H.; Chagas, M.H.; de Oliveira, D.C.; De Martinis, B.S.; Kapczinski, F.; Quevedo, J.; Roesler, R.; Schroder, N.; Nardi, A.E.; Martin-Santos, R.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacol., 2011, 36(6), 1219-26.
101. Lima, N.G.; De Sousa, D.P.; Pimenta, F.C.; Alves, M.F.; De Souza, F.S.; Macedo, R.O.; Cardoso, R.B.; de Morais, L.C.; Melo Diniz Mde, F.; de Almeida, R.N. Anxiolytic-like activity and GC-MS analysis of (R)-(+)-limonene fragrance, a natural compound found in foods and plants. Pharmacol. Biochem. Behav., 2013, 103(3), 450-4.
102. de Almeida, A.A.; Costa, J.P.; de Carvalho, R.B.; de Sousa, D.P.; de Freitas, R.M. Evaluation of acute toxicity of a natural compound (+)-limonene epoxide and its anxiolytic-like action. Brain. Res., 2012, 1448, 56-62.
103. De Almeida, A.A.; de Carvalho, R.B.; Silva, O.A.; de Sousa, D.P.; de Freitas, R.M. Potential antioxidant and anxiolytic effects of (+)-limonene epoxide in mice after marble-burying test. Pharmacol. Biochem. Behav., 2014, 118, 69-78.
104. Bahi, A.; Al Mansouri, S.; Al Memari, E.; Al Ameri, M.; Nurulain, S.M.; Ojha, S. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol. Behav., 2014, 135, 119-24.
105. Galdino, P.M.; Nascimento, M.V.; Florentino, I.F.; Lino, R.C.; Fajemiroye, J.O.; Chaibub, B.A.; de Paula, J.R.; de Lima, T.C.; Costa, E.A. The anxiolytic-like effect of an essential oil derived from Spiranthera odoratissima A. St. Hil. leaves and its major component, beta-caryophyllene, in male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2012, 38(2), 276-84.
106. Braida, D.; Capurro, V.; Zani, A.; Rubino, T.; Vigano, D.; Parolaro, D.; Sala, M. Potential anxiolytic-And antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br. J. Pharmacol., 2009, 157(5), 844-53.
107. Benke, D.; Barberis, A.; Kopp, S.; Altmann, K.H.; Schubiger, M.; Vogt, K.E.; Rudolph, U.; Mohler, H. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropsychopharmacol., 2009, 56(1), 174-81.
108. Shi, S.N.; Shi, J.L.; Liu, Y.; Wang, Y.L.; Wang, C.G.; Hou, W.H.; Guo, J.Y. The anxiolytic effects of valtrate in rats involves changes of corticosterone levels. Evid. Based. Complement. Alternat. Med., 2014, 2014, 325948.
109. World Health Organization International Consortium in Psychiatric Epidemiology. Cross-national comparisons of the prevalences and correlates of mental disorders. Bull. World. Health. Organ., 2000, 78(4), 413-426.
110. Lakhan, S.E.; Vieira, K.F. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr. J., 2010, 9, 42.
111. Peng, Z.; Wang, H.; Zhang, R.; Chen, Y.; Xue, F.; Nie, H.; Chen, Y.; Wu, D.; Wang, Y.; Wang, H.; Tan, Q. Gastrodin ameliorates anxiety-like behaviors and inhibits IL-1beta level and p38 MAPK phosphorylation of hippocampus in the rat model of posttraumatic stress disorder. Physiol. Res., 2013, 62(5), 537-45.
112. Tokumo, K.; Tamura, N.; Hirai, T.; Nishio, H. Effects of (Z)-3-hexenol, a major component of green odor, on anxiety-related behavior of the mouse in an elevated plus-maze test and biogenic amines and their metabolites in the brain. Behav. Brain. Res., 2006, 166(2), 247-52.
113. Costa-Campos, L.; Dassoler, S.C.; Rigo, A.P.; Iwu, M.; Elisabetsky, E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol. Biochem. Behav., 2004, 77(3), 481-9.
114. Rejon-Orantes Jdel, C; Gonzalez-Esquinca, AR; de la Mora, MP; Roldan Roldan, G; Cortes, D. Annomontine, an alkaloid isolated from Annona purpurea, has anxiolytic-like effects in the elevated plus-maze. Planta. Med., 2011; 77(4), 322-7.
115. Peng, W.H.; Wu, C.R.; Chen, C.S.; Chen, C.F.; Leu, Z.C.; Hsieh, M.T. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: Interaction with drugs acting at 5-HT receptors. Life. Sci., 2004, 75(20), 2451-62.
116. Santos Rosa, D.; Faggion, S.A.; Gavin, A.S.; Anderson de Souza, M.; Fachim, H.A.; Ferreira dos Santos, W.; Soares Pereira, A.M.; Cunha, A.O.; Beleboni, R.O. Erysothrine, an alkaloid extracted from flowers of Erythrina mulungu Mart. ex Benth: evaluating its anticonvulsant and anxiolytic potential. Epilepsy. Behav., 2012, 23(3), 205-12.
117. Hazim, A.I.; Ramanathan, S.; Parthasarathy, S.; Muzaimi, M.; Mansor, S.M. Anxiolytic-like effects of mitragynine in the openfield and elevated plus-maze tests in rats. J. Physiol. Sci., 2014, 64(3), 161-9.
118. Cicero Bezerra Felipe, F.; Trajano Sousa Filho, J.; de Oliveira Souza, L.E.; Alexandre Silveira, J.; Esdras de Andrade Uchoa, D.; Rocha Silveira, E.; Deusdenia Loiola Pessoa, O.; de Barros Viana, G.S. Piplartine, an amide alkaloid from Piper tuberculatum, presents anxiolytic and antidepressant effects in mice. Phytomedicine., 2007, 14(9), 605-12.
119. Both, F.L.; Meneghini, L.; Kerber, V.A.; Henriques, A.T.; Elisabetsky, E. Psychopharmacological profile of the alkaloid psychollatine as a 5HT2 A/C serotonin modulator. J. Nat. Prod., 2005, 68(3), 374-80.
120. Han, H.; Ma, Y.; Eun, J.S.; Li, R.; Hong, J.T.; Lee, M.K.; Oh, K.W. Anxiolytic-like effects of sanjoinine A isolated from Zizyphi Spinosi Semen: Possible involvement of GABAergic transmission. Pharmacol. Biochem. Behav., 2009, 92(2), 206-13.
121. Heese, T.; Jenkinson, J.; Love, C.; Milam, R.; Perkins, L.; Adams, C.; McCall, S.; Ceremuga, T.E. Anxiolytic effects of L-theanine--a component of green tea--when combined with midazolam, in the male Sprague-Dawley rat. AANA. J., 2009, 77(6), 445-9.
122. Lee, B.; Sur, B.; Yeom, M.; Shim, I.; Lee, H.; Hahm, D.H. Alphaasarone, a major component of Acorus gramineus, attenuates corticosterone-induced anxiety-like behaviours via modulating TrkB signaling process. Korean. J. Physiol. Pharmacol., 2014, 18(3), 191-200.
123. Girish, C.; Raj, V.; Arya, J.; Balakrishnan, S. Involvement of the GABAergic system in the anxiolytic-like effect of the flavonoid ellagic acid in mice. Eur. J. Pharmacol., 2013, 710(1-3), 49-58.
124. Gilhotra, N.; Dhingra, D. Thymoquinone produced antianxiety-like effects in mice through modulation of GABA and NO levels. Pharmacol. Rep., 2011, 63(3), 660-9.
125. Bouayed, J.; Rammal, H.; Dicko, A.; Younos, C.; Soulimani, R. Chlorogenic acid, a polyphenol from Prunus domestica (Mirabelle), with coupled anxiolytic and antioxidant effects. J. Neurol. Sci., 2007, 262(1-2), 77-84.
126. Yoon, B.H.; Jung, J.W.; Lee, J.J.; Cho, Y.W.; Jang, C.G.; Jin, C.; Oh, T.H.; Ryu, J.H. Anxiolytic-like effects of sinapic acid in mice. Life. Sci., 2007, 81(3), 234-40.
127. Stringer, T.P.; Guerrieri, D.; Vivar, C.; van Praag, H. Plant-derived flavanol (-)epicatechin mitigates anxiety in association with elevated hippocampal monoamine and BDNF levels, but does not influence pattern separation in mice. Transl. Psychiatry., 2015, 5, e493.
128. Cassani, J.; Araujo, A.G.; Martinez-Vazquez, M.; Manjarrez, N.; Moreno, J.; Estrada-Reyes, R. Anxiolytic-like and antinociceptive effects of 2(S)-neoponcirin in mice. Molecules., 2013, 18(7), 7584-99.
129. Ren, L.; Wang, F.; Xu, Z.; Chan, W.M.; Zhao, C.; Xue, H. GABA(A) receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem. Pharmacol., 2010, 79(9), 1337-44.
130. Ishola, I.O.; Chatterjee, M.; Tota, S.; Tadigopulla, N.; Adeyemi, O.O.; Palit, G.; Shukla, R. Antidepressant and anxiolytic effects of amentoflavone isolated from Cnestis ferruginea in mice. Pharmacol. Biochem. Behav., 2012, 103(2), 322-31.
131. A receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Neuropharmacology. 2008, 55(7), 1231-7.
132. Raines, T; Jones, P; Moe, N; Duncan, R; McCall, S; Ceremuga, TE. Investigation of the anxiolytic effects of luteolin, a lemon balm flavonoid in the male Sprague-Dawley rat. AANA J., 2009, 77(1), 33-6.
133. Anderson, W.; Barrows, M.; Lopez, F.; Rogers, S.; Ortiz-Coffie, A.; Norman, D.; Hodges, J.; McDonald, K.; Barnes, D.; McCall, S.; Don, J.A.; Ceremuga, T.E. Investigation of the anxiolytic effects of naringenin, a component of Mentha aquatica, in the male Sprague-Dawley rat. Holist. Nurs. Pract., 2012, 26(1), 52-7.
134. Liu, J.; Zhai, W.M.; Yang, Y.X.; Shi, J.L.; Liu, Q.T.; Liu, G.L.; Fang, N.; Li, J.; Guo, J.Y. GABA and 5-HT systems are implicated in the anxiolytic-like effect of spinosin in mice. Pharmacol. Biochem. Behav., 2015, 128, 41-9.
135. Mohan, M.; Attarde, D.; Momin, R.; Kasture, S. Antidepressant, anxiolytic and adaptogenic activity of torvanol A: an isoflavonoid from seeds of Solanum torvum. Nat Prod Res., 2013, 27(22), 2140-3.
136. Hui, K.M.; Huen, M.S.; Wang, H.Y.; Zheng, H.; Sigel, E.; Baur, R.; Ren, H.; Li, Z.W.; Wong, J.T.; Xue, H. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem. Pharmacol. 2002, 64(9), 1415-24.
137. Ceremuga, T.E.; Johnson, L.A.; Adams-Henderson, J.M.; McCall, S.; Johnson, D. Investigation of the anxiolytic effects of xanthohumol, a component of humulus lupulus (Hops), in the male Sprague-Dawley rat. AANA. J., 2013, 81(3), 193-8.
138. Hirata, H.; Sonoda, S.; Agui, S.; Yoshida, M.; Ohinata, K.; Yoshikawa, M. Rubiscolin-6, a delta opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating sigma1 and dopamine D1 receptors. Peptides, 2007, 28(10), 1998-2003.
139. Seo, J.J.; Lee, S.H.; Lee, Y.S.; Kwon, B.M.; Ma, Y.; Hwang, B.Y.; Hong, J.T.; Oh, K.W. Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2007, 31(7), 1363-9.
140. Leiter, E.; Hitchcock, G.; Godwin, S.; Johnson, M.; Sedgwick, W.; Jones, W.; McCall, S.; Ceremuga, T.E. Evaluation of the anxiolytic properties of myristicin, a component of nutmeg, in the male Sprague-Dawley rat. AANA J., 2011, 79(2), 109-14.
141. Khan, Z.A.; Ghosh, AR. L-arginine abolishes the anxiolytic-like effect of withaferin a in the elevated plus-maze test in rats. African. Journal. Pharmacy. Pharmacol., 2011, 5(2), 234-237
142. Al Rahim, M.; Rimando, A.M.; Silistreli, K.; El-Alfy, A.T. Anxiolytic action of pterostilbene: involvement of hippocampal ERK phosphorylation. Planta. Med., 2013, 79(9), 723-30.
143. Moreira, M.R.; Salvadori, M.G.; de Almeida, A.A.; de Sousa, D.P.; Jordan, J.;Satyal, P.; de Freitas, R.M.; de Almeida, R.N. Anxiolytic-like effects and mechanism of (-)-myrtenol: a monoterpene alcohol. Neurosci. Lett., 2014, 579, 119-24.
144. Wasowski, C.; Marder, M. Central nervous system activities of two diterpenes isolated from Aloysia virgata. Phytomedicine., 2011, 18(5), 393-401.
145. Campos, A.C.; Ferreira, F.R.; Guimaraes, F.S. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors. J. Psychiatr. Res., 2012, 46(11), 1501-10.
146. Campos, A.C.; Ortega, Z.; Palazuelos, J.; Fogaca, M.V.; Aguiar, D.C.; Diaz-Alonso, J.; Ortega-Gutierrez, S.; Vazquez-Villa, H.; Moreira, F.A.; Guzman, M.; Galve-Roperh, I.; Guimaraes, F.S. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. Int. J. Neuropsychopharmacol., 2013, 16(6), 1407-19.
147. Melo, F.H.; Venancio, E.T.; de Sousa, D.P.; de Franca Fonteles, M.M, de Vasconcelos, S.M.; Viana, G.S.; de Sousa, F.C. Anxiolytic-like effect of Carvacrol (5-isopropyl-2-methylphenol) in mice: involvement with GABAergic transmission. Fundam. Clin. Pharmacol., 2010, 24(4), 437-43.
148. Kuribara, H.; Maruyama, Y. The anxiolytic-like effect of ginkgo biloba extract and the constituents assessed by an improved plusmaze test in mice. Japanese. Pharmacol. Ther., 2002, 30(11), 955-962.
149. Kuribara, H.; Weintraub, S.T.; Yoshihama, T.; Maruyama, Y. An anxiolytic-like effect of Ginkgo biloba extract and its constituent, ginkgolide-A, in mice. J. Nat. Prod., 2003, 66(10), 1333-7.
150. Moussaieff, A.; Rimmerman, N.; Bregman, T.; Straiker, A.; Felder, C.C.; Shoham, S.; Kashman, Y.; Huang, S.M.; Lee, H.; Shohami, E.; Mackie, K.; Caterina, M.J.; Walker, J.M.; Fride, E.; Mechoulam, R. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB. J., 2008, 22(8), 3024-34.
151. Cline, M.; Taylor, J.E.; Flores, J.; Bracken, S.; McCall, S.; Ceremuga, T.E. Investigation of the anxiolytic effects of linalool, a lavender extract, in the male Sprague-Dawley rat. AANA J., 2008, 76(1), 47-52.
152. Costa, J.P.; de Oliveira, G.A.; de Almeida, A.A.; Islam, M.T.; de Sousa, D.P.; de Freitas, R.M. Anxiolytic-like effects of phytol: possible involvement of GABAergic transmission. Brain. Res., 2014, 1547, 34-42.
153. da Silveira, N.S.; de Oliveira-Silva, G.L.; Lamanes Bde, F.; Prado, L.C.; Bispo-da-Silva, L.B. The aversive, anxiolytic-like, and verapamil-sensitive psychostimulant effects of pulegone. Biol. Pharm. Bull., 2014, 37(5), 771-8.
154. Jangra, A.; Lukhi, M.M.; Sulakhiya, K.; Baruah, C.C.; Lahkar, M. Protective effect of mangiferin against lipopolysaccharide-induced depressive and anxiety-like behaviour in mice. Eur. J. Pharmacol., 2014, 740, 337-45.